Somatuline Depot

Somatuline Depot is a brand name of lanreotide, approved by the FDA in the following formulation(s):

SOMATULINE DEPOT (lanreotide acetate - injectable; subcutaneous)

• 
  Manufacturer: IPSEN PHARMS
  
  Approval date: August 30, 2007
  
  Strength(s): EQ 120MG BASE ^[RLD], EQ 60MG BASE ^[RLD], EQ 90MG BASE ^[RLD]

Has a generic version of Somatuline Depot been approved?

No. There is currently no therapeutically equivalent version of Somatuline Depot available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Somatuline Depot. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Sustained release of peptides from pharmaceutical compositions
  Patent 5,595,760
  Issued: January 21, 1997
  Inventor(s): Cherif-Cheikh; Roland
  Assignee(s): Delab
  The invention features a method of administering a peptide to a patient and delivering the peptide continuously over an extended period of time of at least three days by obtaining a solid pharmaceutical composition including a soluble, gelable salt of the peptide and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier, and parenterally administering the solid composition to the patient in one injection, wherein the solid composition automatically forms a gel after interaction with the patient's bodily fluids and releases the peptide continuously within the patient over an extended period of at least three days.
  
  Patent expiration dates:
  
  
  • March 8, 2020
    
    ✓ 
    Patent use: METHOD OF ADMINISTERING LANREOTIDE ACETATE
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 30, 2012 - NEW CHEMICAL ENTITY
  
  
  • March 4, 2014 - EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
  
  
  • August 30, 2014 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Somatuline Depot Consumer Information (Drugs.com)
• Somatuline Depot Consumer Information (Wolters Kluwer)
• Somatuline Depot Consumer Information (Cerner Multum)
• Somatuline Depot Advanced Consumer Information (Micromedex)
• Somatuline Depot AHFS DI Monographs (ASHP)
• Lanreotide Consumer Information (Wolters Kluwer)
• Lanreotide Consumer Information (Cerner Multum)
• Lanreotide Subcutaneous Advanced Consumer Information (Micromedex)
• Lanreotide Acetate AHFS DI Monographs (ASHP)